Research programme: multidrug-resistant antibiotics - Peptilogics

Drug Profile

Research programme: multidrug-resistant antibiotics - Peptilogics

Alternative Names: Antimicrobial peptides - Peptilogics; eCAPS - Peptilogics; engineered Cationic Antimicrobial Peptides - Peptilogics; PLG 0206

Latest Information Update: 05 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Peptilogics
  • Class Anti-infectives; Antibacterials; Antimicrobial cationic peptides
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 01 Jun 2018 PLG 0206 receives Qualified Infectious Disease Product status for Bacterial infections in USA
  • 29 Sep 2017 Peptilogics intends to file an IND application and initiate clinical development of PLG 0206 for Bacterial infections in 2018
  • 29 Sep 2017 Preclinical trials in Bacterial infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top